U.S. markets open in 8 hours 10 minutes

Zentalis Pharmaceuticals, Inc. (ZNTL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
40.26+4.13 (+11.43%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close36.13
Open36.84
Bid0.00 x 900
Ask0.00 x 1100
Day's Range35.68 - 40.29
52 Week Range22.00 - 61.29
Volume264,990
Avg. Volume384,261
Market Cap1.635B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est58.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021
      GlobeNewswire

      Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021

      NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that initial clinical data from the Phase 1 portion of its Phase 1/2 monotherapy trial of ZN-c3, the Company’s WEE1 inhibitor, in advanced solid tumors has been selected for presentation at the upcoming virtual American Association for Cancer Research (AACR) Annual Meeting 2021. AACR is being held April 10-15 and May 17-21. About ZN-c3 ZN-c3 is an oral inhibitor of WEE1 in development for the treatment of advanced solid tumors. The inhibition of WEE1, a DNA damage response protein, aims to generate sufficient DNA damage in cancer cells, causing cell death, thereby preventing tumor growth and potentially causing tumor regression. Zentalis is currently conducting a Phase 1/2 clinical trial in patients with advanced solid tumors and expects to report data from the Phase 1 portion at the AACR Annual Meeting 2021. In addition, the Company is also conducting a Phase 1b trial evaluating ZN-c3 in combination with chemotherapy in patients with advanced ovarian cancer, with plans to initiate a Phase 2 trial investigating ZN-c3 as a monotherapy in patients with uterine serous carcinoma in 2021. About Zentalis Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego. For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the development, potential, safety, efficacy, and regulatory and clinical progress of our product candidates in the Unites States and globally, plans and timing for the initiation of and the release of data from our clinical trials, including the presentation of initial clinical data from the Phase 1 portion of our Phase 1/2 clinical trial of ZN-c3 at AACR Annual Meeting 2021, and our ability to meet other key milestones, the anticipated direct and indirect impact of COVID-19 on our business and operations, and the sufficiency of our cash and cash equivalents. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidate; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Investor Contact:Thomas HoffmannSolebury Trout1.646.378.2931thoffmann@soleburytrout.com Media Contact:Julia DeutschSolebury Trout1.646.378.2967jdeutsch@soleburytrout.com

    • Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors
      GlobeNewswire

      Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors

      NEW YORK & SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Enoch Kariuki, PharmD, to its Board of Directors. Dr. Kariuki is a highly accomplished finance executive, bringing over a decade of deep expertise in life sciences investment banking, strategic advising and business development to Zentalis. “We are pleased to welcome Enoch to our Board of Directors, and believe his experience as a financial leader in the healthcare sector will offer invaluable perspective for our growing organization,” said Dr. Anthony Sun, Chairman and Chief Executive Officer at Zentalis Pharmaceuticals. “Over the course of his career, Enoch has played a pivotal role in follow-on offerings and multibillion-dollar mergers and acquisitions, and we look forward to applying his guidance and learnings to Zentalis’ corporate financial strategy.” Dr. Kariuki most recently served as Chief Financial Officer at VelosBio, a clinical-stage oncology-focused biopharmaceutical company, which was acquired by Merck. At VelosBio, he led all finance-related and investor relations functions. Prior to VelosBio, he served as Senior Vice President of Corporate Development at Synthorx. During his tenure, he led the company’s IPO as well as business development efforts leading up to its acquisition by Sanofi. Previously, Dr. Kariuki was Vice President at H.I.G. Capital, where he invested in and served on the boards of multiple life sciences companies. Earlier in his career, Dr. Kariuki held various roles in investment banking at Leerink Partners and UBS Investment Bank. He completed a Post-Doctoral Fellowship in R&D Strategy and Analytics at Bristol Myers Squibb and was a Pharmacist at CVS Caremark. Dr. Kariuki received an MBA from the Tuck School of Business at Dartmouth College and a PharmD from Texas Southern University. “I am honored to join Zentalis’ Board and to serve as the Chair of the Audit Committee,” commented Enoch Kariuki, PharmD. “I am eager to work closely with the Zentalis team to provide collaborative and meaningful contributions as they navigate bringing potentially differentiated cancer therapeutics to patients.” About Zentalis Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego. For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding Dr. Kariuki’s expected contributions to our board, our growth strategy and our expectations surrounding the development, potential, safety, efficacy, and regulatory and clinical progress of our product candidates in the Unites States and globally. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidate; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Investor Contact:Thomas HoffmannSolebury Trout1.646.378.2931thoffmann@soleburytrout.com Media Contact:Julia DeutschSolebury Trout1.646.378.2967jdeutsch@soleburytrout.com

    • Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
      GlobeNewswire

      Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

      NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences. Presentation Details: Event: Guggenheim Healthcare Talks 2021 Oncology DaysDate: Friday, February 12, 2021Time: 1:30 p.m. EST Event: SVB Leerink 10th Annual Global Healthcare ConferenceDate: Wednesday, February 24, 2021Time: 10:00 a.m. EST Live webcasts from the Guggenheim and SVB Leerink fireside chats will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the events, archived webcasts will be available on the Zentalis website. About Zentalis Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego. For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals. Investor Contact: Thomas HoffmannSolebury Trout1.646.378.2931thoffmann@soleburytrout.com Media Contact: Julia DeutschSolebury Trout1.646.378.2967jdeutsch@soleburytrout.com